Anti-Jo-1 (27.6%, n = 8), anti-MDA5 (27.6%, n = 8), anti-Ro-52 (24.1%, n = 7), anti-PL-7 (20.7%, n = 6), and anti-OJ (13.8%, n = 4) were the most frequently encountered antibodies in patients diagnosed with CADM. This evidence concerns the gene TRIM21 and clinically amyopathic dermatomyositis.